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Hiromi Nakamura: Correlation between desmoglein-2, oral epithelial dysplasia and tumor depth 
of invasion in oral squamous cell carcinoma. 
(Under the direction of Ricardo Padilla) 
 
Objective: To characterize the expression, distribution, and intensity of desmoglein-2 in 
oral epithelial dysplasia and squamous cell carcinoma, and correlate its expression with the depth 
of invasion of the tumor in order to determine whether it can be used as a prognostic or staging 
parameter. 
Methods: This pilot study was reviewed and approved by our institution’s IRB Committee 
in 2018.  Twenty five archival tissue samples from the files of the  UNC School of Dentistry Oral 
and Maxillofacial Pathology Laboratory were used.  The test cases were selected among those 
diagnosed as oral epithelial dysplasia and oral squamous cell carcinoma. Cases with normal 
overlying epithelium were selected as controls. Immunohistochemistry for desmoglein-2 antibody 
was performed on each case. The results were evaluated, tabulated, and analyzed for expression 
of desmoglein-2. 
Results: There was no significant difference in the intensity score and distribution of 
desmoglein-2 among the test and control groups. There was no correlation between the degree of 
oral epithelial dysplasia or depth of invasion of oral squamous cell carcinoma and the intensity or 
distribution of the cell adhesion molecule desmoglein-2. 
Conclusions: Our preliminary results do not support the use of desmoglein-2 expression as 
a prognostic or staging parameter for oral epithelial dysplasia or oral squamous cell carcinoma. 
iv 
To my mentors and friends, I couldn’t have done this without you. 
Thank you for all of your support along the way 
 
 
                                                        























First of all, I would like to show my gratitude and appreciation to Dr. Ricardo Padilla, my 
program director at Oral and Maxillofacial Pathology at UNC Adams School of Dentistry. I am 
very fortunate to have him as my director, not only because of his enthusiastic guidance and 
tremendous support, but also because of his professional ethics and passion for Oral Pathology. 
He always emphasizes that patient care comes first and that we have to make progress for the 
best patient care. He is always willing to help me with what I have learned in my residency. 
I am also very thankful for Dr. Valerie Murrah, Department Chair at Oral and 
Maxillofacial Pathology at UNC. She constantly encouraged me in many aspects of my 
residency for the past three years. Her diligence, enthusiasm, and passion for her work has made 
a huge impact on my residency life. She has always inspired me in the advancement of my 
studies and research. 
I am very fortunate to have these two esteemed mentors in my residency. This is one of 
the best experiences I have had in my life. 
I also would like to acknowledge Dr. Andres Flores, who had completed the residency at 
Oral and Maxillofacial Pathology at UNC School of Dentistry in 2018. He is my role model and 
forerunner in the path I have been walking. I truly appreciate his tremendous support for my 
residency. 
I would also like to recognize Dr. Alice Curran, who retired from our department in 2019, 
for her guidance and support
vi 
Lastly, I want to express my appreciation to my co-residents, my friends, and my 
husband for their tremendous support. This accomplishment would not be possible without all of 




TABLE OF CONTENTS 
 
LIST OF TABLES ......................................................................................................................... ix 
LIST OF FIGURES ........................................................................................................................ x 
LIST OF ABBREVIATIONS ........................................................................................................ xi 
LITERATURE REVIEW ............................................................................................................... 1 
Oral Epithelium ........................................................................................................................... 1 
Desmosomes................................................................................................................................ 1 
Cell Adhesion .............................................................................................................................. 2 
Cell adhesion molecules .............................................................................................................. 2 
Oral epithelial dysplasia .............................................................................................................. 5 
Dysplasia ..................................................................................................................................... 6 
OED progression into OSCC ...................................................................................................... 7 
Oral squamous cell carcinoma .................................................................................................... 8 
Depth of Invasion (DOI) ........................................................................................................... 12 
AIMS AND OBJECTIVES .......................................................................................................... 14 
MATERIALS AND METHODS .................................................................................................. 15 
Specimen Selection ................................................................................................................... 15 
Inclusion and Exclusion Criteria ............................................................................................... 15 
Data Collection and Processing................................................................................................. 17 
Study Procedures ....................................................................................................................... 17
viii 
Analysis of Images .................................................................................................................... 17 
Data Analysis ............................................................................................................................ 17 
RESULTS ..................................................................................................................................... 18 






LIST OF TABLES 
 
Table 1: WHO criteria for epithelial dysplasis…………………………………………………..6 
Table 2: Definition of 8TH edition AJCC TNM. Definition of primary tumor (T-
category)………………….…………………………………………………………….. 12 
 
Table 3: DSG-2 intensity scores of per group…………………………………………………...19 
  
x 
LIST OF FIGURES 
  
Figure 1: Oral epithelial dysplasia 2-tier and 3-tier grading system..…………………………..7 
Figure 2: The expression of desmoglein-2…………………………..………………………...19 





                                                             

















LIST OF ABBREVIATIONS 
AJCC  The American Joint Committee on Cancer 
DOI  Depth of Invasion                                        
Dsc       Desmocollin                                   
Dsg  Desmoglein  
ECM  Extracellular Matrix 
GLUT  Glucose Transporter 
HPV  Human Papillomavirus 
IARC  International Agency for Research  
Ig  Immunoglobin 
MAPK  Mitogen Activated Protein Kinase 
NCI  National Cancer Institute  
OED  Oral Epithelial Dysplasia 
OMP  Oral and Maxillofacial Pathology 
OSCC  Oral Squamous Cell Carcinoma 
SEER  Surveillance, Epidemiology, and End Research 
SSE  Stratified Squamous Epithelium 
TNM  Tumor, Node, and Metastasis 
TPL  Translational Pathology Laboratory 





 The oral cavity is the initial functional anatomical site of the alimentary tract and plays a 
large number of roles related to biological and social funtions.  The oral cavity is lined by oral 
mucosa, which is composed of a superficial layer of stratified squamous epithelium (SSE) and an 
underlying layer of connective tissue that contains salivary glands, neurovascular bundles, and 
other adnexal structures. Tilakalatne has defined oral epithelial dysplasia (OED) as “a spectrum of 
architectural and cytological changes that are associated with increased risk of progression to oral 
squamous cell carcinoma (OSCC)”.(1)  There are several risk factors for the development of 
precancerous and cancerous changes, and the outcome for patients suffering of them is varied but 
in part influenced by the stage of their disease and treatment modality. The American Joint 
Comission of Cancer (AJCC) has released its 8th edition guide for staging of cancer.(2)  The depth 
of invasion of the tumor (DOI) is a new parameter that is now part of the staging system in cases 
for OSCC. In this project,  we aim to evaluate the relationship between grade of OED and DOI of 
OSCC. 
Desmosomes 
 In the oral epithelium, desmosomes are highly specialized and organized intercellular 
junctions that facilitate  adhesion between keratinocytes. When the desmosomal adhesion is 
weakened or lost, acantholysis occurs. In this process, the keratinocytes separate from each other 
and the epithelial integrity is lost. It has been reported that alteration of desmosomal adhesion can
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contribute to invasion of some malignancies, such as OSCC and cutaneous squamous cell 
carcinoma.(3,4)
 Cell Adhesion 
 Cell adhesion molecules have been recognized to play significant roles in various 
physiological phenomena, such as cell growth, proliferation, differentiation, migration, and tumor 
progression.(5–7) Importantly, cell adhesion molecules are involved in cancer progression and 
metastasis via interaction between cells and between associated matrices. Numerous studies have 
been published to investigate the mechanism of tumor progression, growth, and metastasis.(8–11) 
The immunoglobulin (Ig) superfamily is one of the largest cell surface protein and soluble protein 
families. The Ig superfamily binds to diverse ligands, and this binding leads to various types of 
functions including cell adhesion.(12,13)  
In studies of cancer progression, multiple different types of the Ig superfamily are being 
investgated and identified. Subsequently, therapeutic methods have been developed. For example, 
Min et al developed CAR T therapy for advanced thyroid cancer using anti-ICAM agents due to 
the higher expression of ICAM in thyroid cancer.(14)  
Cell adhesion molecules  
 Different types of adhesion molecules participate in the growth and progression of specific 
types of cancers.  
1) Integrins: 
Integrins are large cell adhesion molecules (160KDa) and are expressed in all cells except 
erythrocytes. They have a heterodimeric composition including  two different chains, α-, and β- 
that form receptors and bind to the extracellular matrix (ECM).(11)  The integrin receptors mediate 
various physiological and pathological phenomena that lead to the progression and metastasis of 
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tumors. For example, higher expressions of integrins αvβ3, α5β1 and αvβ6  are detected in some 
solid tumors, whereas very low levels of expression are observed in normal epithelium.  
Expression of these integrins is correlated with tumor progression in various neoplasms, such as 
melanoma (αvβ3, α5β1), prostate and pancreatic (αvβ3), cervical (αvβ3, αvβ6), non-small-cell-
lung carcinoma (α5β1), and colon (αvβ6). In addition, in tumor-associated cells, integrins 
contribute to various physiological functions, such as anti-apoptosis, angiogenesis, the growth of 
fibrous or connective tissue, and activation of cytokine receptors. (15)  
Integrin-targeted cancer therapy has been studied,  and drugs addressing their effects have been 
tested in clinical trials. For example, Hill et al showed that rapamysin, an integrin αvβ3-targeted 
dendrimer, reduced the progression and metastasis in prostate cancer.(16)  
2) Selectins 
Selectins are adhesion molecules that contain glycoproteins with a lectin-like domain. This 
domain binds to specific carbohydrate structures. Selectins are divided into three groups, L-
selectin (CD62L), P-selectin (CD62P), and E-selectin (CD62E).  They are expressed on cell 
surfaces of almost all leukocyte subpopulations, platelets, and endothelial cells, respectively.(17) 
Various studies have revealed that selectins play a crucial role in tumor progression and 
metastasis. Selectins not only mediate tumor cell adhesion but actively contribute to 
metastasis.(18,19)  
Breat cancer therapy, targeting selectin, has been developed due to the increased expression of 
p-selectin in the breast cancer cells.(19)  
3) Cadherins 
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 Cadherins are calcium-dependent cell-cell adhesion molecules  expressed in most normal 
epithelial tissues. There are at least three groups of cadherins; epithelial cadherin (E-cadherin), 
neural cadherin (N-cadherin), and placental cadherin (P-cadherin).  
E-cadherin has been studied in the progression and metastasis of cancer. Loss or downregulated 
expression of E-cadherin is frequently observed in aggressive metastatic ductal carcinoma of the 
breast.(20) However, this finding is not universal. Padmanaban et al showed that “E-cadherin 
promotes metastasis in diverse models of invasive ductal carcinomas” of the breast. “While loss 
of E-cadherin increased invasion, it also reduced cancer cell proliferation and survival, circulating 
tumour cell numbers, seeding of cancer cells in distant organs and metastasis outgrowth”.(21)  
Hauselmann et al also have shown that E-cadherin is required for hematogenous metastasis within 
the tumor microenvironment by orchestrating the adhesion and activation of monocytes.(22)  
Desmogleins (Dsgs) are cell adhesion molecules that are part of the family of cadherins, 
and consist of four isoforms, Dsg-1, Dsg-2, Dsg-3, Dsg-4.(23)  Studies have suggested that loss of 
Dsg-3 is a common event in OSCC.(24,25) In contrast, Chen et al reported that Dsg-3 is 
overexpressed in head and neck squamous cell carcinoma.(26)  
Xin et al investigated Dsg-1, 2, 3 and Desmocollin-2 (Dsc-2) in 51 cases of OSCC. Their 
results showed that Dsg-2 is expressed in basal cells, and Dsg-3 is expressed in both suprabasal 
and basal cells. In OSCC, Dsg-3 and Dsc-2 expression were decreased in the high grade (poorly 
differentiated) group, whereas Dsg-1 or Dsg-2 expression was not correlated with grade. 
Moreover, in OSCC, Dsg-2 overexpression was observed in the cytoplasm, but not in basal 
cells.(27) This is in contradiction with the findings of Teh et al  of an “isoform switch” between 
Dsg-2 and Dsg-3,(25) however, it fits the finding by Hartlieb et al, who state that Dsg2 is “less 
important than Dsg3” in keratinocyte cohesion.(28)  
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Dsg-2 has been investigated in different types of diseases. El-Amraoui published the role 
of Dsg-2 in cardiomyopathy.(29) In Crohn’s disease, decreased Dsg-2 expression was observed to 
play a role in protection of the intestinal epithelium.(30) More recently, Dsg-2 is emerging as an 
adhesion molecule of interest in cancer research. Hutz et al documented that the silencing of the 
Dsg-2 in pancreatic cancer cells enhanced invasion and hypothesized that Dsg-2 may act as a tumor 
suppressor.(31)  
On the other hand, Overmiller et al revealed the role of Dsg-2 molecules in the progression 
of head and neck squamous cell carcinoma. They documented that Dsg-2 overexpression in head 
and neck squamous cell carcinoma and the modulation of extracellular vesicles by the processed 
fragment of Dsg-2. This modulation potentially leads to tumor progression.(32)  
Oral epithelial dysplasia 
Oral epithelia dysplasia (OED) is diagnosed histologically and defined by the World Health 
Organization (WHO) as a precancerous lesion of SSE. The characteristics of oral epithelial 
dysplasia defined by WHO are architectural and cytological alterations, incuding irregular 
epithelial stratification, loss of polarity of basal cells, drop-shaped rete ridges, increased number 
of mitotic figures, abnormally superficial mitotic figures, premature keratinization in single cells 









Table 1: World Health Organization (WHO) criteria for epithelial dysplasia (2017) (34) 
Architectural changes Cellular changes 
Irregular epithelial stratification              Abnormal variation in nuclear size    
(Anisonucleosis) 
Loss of Polarity of basal cells                     
 
Abnormal variation in nuclear shape 
(nuclear pleomoephism) 
Drop-shaped rete ridges Abnormal variation in cell size                                                               
(anisocytosis) 
Increased number of mitotic figures  Abnormal variation in cell shape 
(cellular pleomorphism) 
Abnormal superficial mitosis             Increased nuclear-cytoplasmic ratio 
Premature keratinization in single 
Cells (dyskeratosis)         
Atypical mitotic figures 
Keratin pearls within rete ridges.              Increased number and size of nucleoli 
Loss of epithelial cell cohesion**.            Hyperchromasia 
** Included in the 2017 WHO classification. WHO: World Health Organization 
 
Dysplasia                                                    
A) Two-tier and three-tier grading systems 
Two grading systems are currently in use for OED classification, a two-tier one and a three-tier 
one.  The WHO (34) recommends the 2-tier system (low and high grade) for all epithelial tissues 
with the exception of oral mucosa.  The two-tier system is the predominant one used in all other 
organ systems in order to simplify and promote a uniform standard among clinicians and 
pathologists.  For OED, the three-tier system is still the convention but is under evaluation at this 





FIGURE 1: Oral epithelial dysplasia  (35) 
 
 
OED progression into OSCC 
Zaini et al. investigated the correlation between OED using the 3-tier system and malignant 
transformation. Their results showed that 13.3% of mild, 33.3% of moderate, and 46.7% of severe 
dysplasias progressed to OSCC . However, in the same study, 6.7 % of non-dysplastic lesions 
transformed to OSCC.(36)   
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 Muller states that the 3-tier-grading system does not predict OED progression to OSCC 
any better than the 2-tier system. Mild dysplasia is defined as atypia limited to the lower third of 
the epithelium.  Moderate dysplasia is defined as atypia extending from the basal cells to the 
middle third of the epithelium.  Severe dysplasia is defined as atypia extending from the basal cells 
to the upper third of the epithelium.  The problem is that some pathologists may categorize  
moderate OED as low-grade, whereas other pathologists may categorize the same “moderate” 
OED as “high” in 2-tier grading.(35) 
Oral squamous cell carcinoma 
1) Epidemiology and etiology: Oral cancer is the eleventh most common cancer 
worldwide.(33) It is the eighth most common cancer among males, and the 14th most common 
among females in the United States.(37) More than 90% of oral cancers are squamous cell 
carcinoma (OSCC).(38)  
OSCC affects approximately 54,000 individuals each year in the United States and 45,000 
new cases are diagnosed annually worldwide.(39,40) The incidence and mortality are very high 
(8.9 and 5.7 (per 100,000) respectively) in eastern and southeastern Asian countries such as India, 
China, and Taiwan due to smokeless tobacco, chewing of betel quids and cigarette smoking. OSCC 
affects more males than females (1.5:1), probably due to differences in the use of smoking and 
heavy alcohol consumption, which are the most common risk factors for OSCC. The tongue is the 
most common site.(33,37)  
(i) Tobacco use: Cigarette smoking, and smokeless tobacco consumption are 
risk factors for the development of OSCC. According to the WHO, 
approximately 8 million deaths per year are caused by tobacco smoking 
worldwide, with 1.2 million annually caused by second-hand smoke.(41) In 
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2018, approximately 34.2 million of the U.S. population over 18 years of age 
were smokers.  Tobacco and  its products contain more than 60 different 
carcinogens.(42) These carcinogens are known to cause gene mutations that 
can lead to tumorigenesis. Gene mutations cause the loss of normal function 
in cells, such as cell growth, proliferation, and apoptosis. This may lead to 
overgrowth of “abnormal” cells resulting in neoplasia. The best described 
carcinogenic mutation is that of tumor suppressor gene p53 (encoded to 
TP53 in humans) although multiple other gene mutations in tumors have 
been identified.(43) The glucose transporter family (GLUTs) is a protein 
family that involves glucose transportation through the cell membranes. 
GLUT-1 expression is upregulated in malignant cells, which probably leads 
to increased cell proliferation. Azad et al showed that GLUT-1 significantly 
correlated with tobacco-related human oral carcinoma.(44)  
(ii) Alcohol consumption: Both ethanol and acetaldehyde are categorized as  
carcinogens by the International Agency for Research on Cancer (IARC). 
They are associated with various types of cancer, such as oral, pharyngeal, 
laryngeal, esophageal, liver, pancreatic, colorectal and others.(45) They 
categorized individual consumption based on the amount per day: light (less 
than 12.5g of alcohol per day), moderate (more than 12.5 less than 50g), and 
heavy (more than 50g per day) drinkers. Compared to non-alcohol drinkers, 
moderate drinkers have approximately a 1.8-fold higher risk of oral and 
pharyngeal cancer, and 1.4-fold risk of laryngeal cancer development.  
Heavy drinkers have a 5-fold higher risk of oral and pharyngeal cancer, and 
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a 2.6 higher risk of laryngeal cancer.(45) The mechanism of alcohol-induced 
carcinogenesis has not been fully elucidated. However, multiple different 
types of complex events have been suggested to be involved in cancer 
development and progression. These events include genotoxic effects of 
acetaldehyde, increased estrogen hormone, cellular stress, and changes in 
folate metabolism.(46–49) 
(iii) Human papillomavirus: Human Papillomavirus (HPV) infection with high 
risk types (HPV 16 and 18, and others) has been reported as a risk factor for 
squamous cell carcinoma, especially lesions that initiate from the 
oropharyngeal region. (50,51) However, the reported high-risk HPV OSCC 
is a relatively lower percentage (approximately 1-6%) of the OSCC 
cases.(52,53)  HPV 16 and HPV 18 are the most common high-risk 
genotypes associated with carcinogenesis.(50)  The E6 and E7 genes of HPV 
have been identified to contribute to HPV-induced cancer. The E6 protein 
degrades p53 tumor suppressor oncoproteins and E7 binds to the Rb, another 
tumor suppressor oncoprotein.(54) HPV immunization has been adopted in 
many countries and is highly effective. Initially, two types of vaccines, 
bivalent (2vHPV: target HPV16/18) and quadrivalent (4vHPV: target HPV 
16/18/6/11) were available, and currently, a 9-valent vaccine (9vHPV) is 
available that induces immunity to infection by HPV types 6, 11, 16, 18, 31, 
33, 45, and 52.(54) 
2) Early stage detection and diagnosis: Despite current developments and advances of 
OSCC diagnosis, treatment, and follow-up exams, the 5-year-survival rate has not improved and 
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has remained at approximately 50% for the past three decades.(55)  Early detection and accurate 
diagnosis of OSCC are crucial to decrease the mortality and improve prognosis of the patients. 
The ability to make an accurate diagnosis at an early stage of OSCC requires sufficient 
experience and knowledge.(56) 
 Multiple lesions such as leukoplakia, erythroleukoplakia, and lichen planus might mimic 
the early stage of OSCC, complicating early precise diagnosis. A variety of health care 
providers, including dentists, dental hygienists, general practitioners, oncologists, surgeons, and 
nurses may perform visual screening after appropriate training.(56)  
3) 5-year survival rates: According to the National Cancer Institute (NCI) that maintains 
the Surveillance, Epidemiology, and End Results (SEER) Program database, patients with 
localized OSCC have better 5-year-survival rate compared to those with regional and metastases. 
The survival rate is also dependent on the primary site of the OSCC.  For tongue OSCC, the 5-
year-survival rates is 81 percent for patients with localized disease, 68 percent for those with 
regional extension, and 39 percent for the ones with distant metastases. With floor of mouth 
lesions, the rates are 77 percent for localized disease, 38 percent for regional disease, and 20 
percent for distant metastases.(57)  
4) Treatment and management: 
Treatment for OSCC includes mainly surgery, chemotherapy, radiation, and chemoradiotherapy.  
Recently, immunotherapy and proton beam radiation have started to enter the treatment realm, 
especially for refractory and advanced cases. Immunotherapy involves the stimulation of specific 
components of the immune system, such as T and B lymphocytes.  In the last two decades, 
advances in molecular biology have contributed significantly to the development of novel 
treatment and management strategies for OSCC.(58)  
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Depth of Invasion (DOI) 
In the 8th edition of the AJCC Cancer Staging Manual, one of the most crucial alterations is the 
incorporation of DOI, and it has been added to the T-staging category in the TNM classification. 
(2) 
TABLE 2. Depth of invasion 
 
Table 2: Defintions of 8th edition AJCC TNM. Definition of primary tumor (T-category). 
The AJCC considers DOI to be “the actual mass present beneath the basement membrane, 
or in case of ulceration or exophytic lesions, the theoretical reconstruction of the basement 
membrane”.(2) The definition of DOI or the measurement of DOI is the distance from the 
basement membrane of the adjacent intact epithelium to the deepest point of the invasive tumor. 
(59) 
DOI has been associated with cancer progression and considered to be the best 
histopathological predictor for regional metastasis.(60–64) 
DOI is one of the factors that correlates with tumor progression and chance of regional 
metastasis. Based on the examination of 407 cases of conventional oral tongue SCC, Berdogo et 
____________________________________________________________________________________________ 
T category  T Criteria 
____________________________________________________________________________________________ 
   TX                      Primary tumor cannot be assessed 
   Tis                          Carcinoma in situ 
   T1                          Tumor ≤ 2cm, ≤ 5mm DOI 
   T2                          Tumor ≤ 2cm, DOI > 5mm and  10 mm or tumor > 2cm but ≤ 4 cm, and ≤ 10 mm DOI 
   T3                          Tumor > 4 cm, or any tumor  > 10mm DOI 
   T4                         Moderately advanced or very advanced local disease 
   T4a                        Moderately advanced local disease (lip) Tumor invades through cortical bone or  
   involves the inferior alveolar nerve, floor of mouth, or skin or face (i.e. chin or nose, 
   or oral cavity) Tumor invades adjacent structures only (e.g., through cortical bone of the 
   mandible or maxilla, or involves the maxillary sinus or skin of the face). None erosion 
   bone/tooth socket (alone) by a gingival primary is not sufficient to classify a tumor as 
   T4 
   T4b                        Tumor invades masticator space, pterygoid plates or skull base and/or encases the 
   internal carotid artery 
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al have conclude that there are other factors, such as deep margin status and absence or minimal 
residual carcinoma in the biopsies that may influence the pT staging of OSCC. They have 
mentioned that the method of DOI measurement also affects the results.  They concluded that 
accurate DOI measurement in biopsies may be impossible if the specimen is fragmented or if 
normal mucosa or intrinsic tongue musculature is absent.(65)   
Based on  these  studies,  we investigated  the role of Dsg-2  in OED and OSCC DOI.  
Understanding  how this cell adhesion molecule is involved in  OSCC  may  provide insight  into 
possible  staging  and therapeutic strategies. 
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AIMS AND OBJECTIVES 
Aim 
To correlate the distribution and intensity of expression of Dsg-2 with the degree of OED 
and the DOI of OSCC. 
Hypothesis 
Null Hypothesis: There is no statistically significant difference in the distribution and 
intensity of Dsg-2 with the degree of OED or the DOI of OSCC. 
Alternative Hypothesis: There is statistically significant differenc in the distribution and 











MATERIALS AND METHODS 
This study protocol was reviewed and approved by the University of North Carolina at 
Chapel Hill Institutional Review Board under the study number 18-0552. All study procedures 
were performed in accordance with the Declaration of Helsinki and Research Committee 
Regulations. The study was designed as a pilot retrospective study.  
Specimen Selection 
The study cases consisted of residual archival material from the UNC Oral and 
Maxillofacial Pathology Laboratory. The control group comprised 5 cases containing no 
epithelial abnormalities.  The test cases were diagnosed as OSCC or OED.  Five cases for each 
of the following abnormal epithelial groups were selected:  
• Low-grade OED 
• High-grade OED 
• OSCC with DOI less than 5 mm 
• OSCC with DOI greater than 5 mm 
 
Inclusion and Exclusion Criteria 
Inclusion Criteria: 
              For inclusion in this study, the specimens selected met the following criteria: 
1. All cases had sufficient residual tissue in the formalin-fixed paraffin-embedded 
tissue block for additional sections without exhausting the block.
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2. Oral squamous cell carcinoma specimens with depth of invasion ranging > 0 to 15 
mm 
a) OED, low grade 
b) OED, high grade 
c) OSCC with DOI <5mm (superficial) 
d) OSCC with DOI >5mm (deeply invasive) 
e) The control group comprised 5 cases containing no epithelial abnormalities. 
Exclusion Criteria: 
                Any of the following was regarded as a criterion for exclusion from the study: 
1. Patients with radiation or/and chemotherapy for cancer or any other condition 
prior to biopsy 
2. Patients with previous history of a biopsy at the same location 
3. Patients with previous history of tumor/cancer at the same location 
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Data Collection and Processing 
After obtaining Institutional Review Board approval for use of archived tissue samples, 
all samples were reviewed and assigned to a group by one board-certified oral and maxillofacial 
pathologist (OMP) and one OMP resident for consensus on diagnoses. DOI was measured for 
each specimen. Paraffin embedded tissues were cut into 4 µm thick sections and placed on 
positive charged slides. All cases were immunostained with appropriate antibody against 
desmoglein-2 using standard immunohistochemistry technique. 
Study Procedures 
Formalin-fixed, paraffin-embedded samples of OSCC, low and high OED, and controls 
were stained for desmoglein-2 immunostaining. The peroxidase blocking was performed for 20 
minutes. Anti-desmoglein-2 antibody was used (Catalog#32-6100, Thermo Fisher Scientific, 
Waltham, MA, USA).  
Analysis of Images:  
After immunostaining, the slides were scanned using the Aperio ScanScope FL (Leica 
Biosystems, Wetzlar, Germany) at 20X and the images were archived in the Translational 
Pathology Laboratory (TPL) eSlide Manger database (Leica Biosystems, Wetzlar, Germany). 
Desmoglein-2 expression was performed with blinded scoring using a five-point intensity scale 
(0=none; 1=very weak; 2=weak, 3=moderate, 4=strong).   
Data Analysis:  
After collecting the scores for each group, Student’s t-test was performed to calculate 






The difference in expression of Dsg-2 was not statistically significant among all groups. In low 
and high OED groups, decreased expression of Dsg-2 was observed compared to the control 
group.  The expression in the high grade OED group was lower than that of the low OED group.  
(Score averages for control, low and high dysplasia = 1.8, 1.4, and 1 respectively; standard 
deviations =0.37, 0.24, 0 respectively). Based on p values, there were no significant differences 
among these three groups, however, the tendency of the expression favored the acceptance of the 
alternate hypothesis. (Figure 1) 
 Decreased expression of Dsg-2 was not detected in the DOI>5 group (Ave. =2.2) 
compared to the DOI<5 group (Ave.=1.6), however, again, there was no significant difference 
among these groups (p= 0.37).  
 Overall, there was no significant difference in the staining intensity score among these 5 
groups. 




TABLE 3: intensity scores 
Groups Control Low grade High grade DOI<5 DOI>5 
  1 1 1 2 1 
  2 1 1 1 4 
  3 1 1 2 1 
  1 2 1 2 2 
  2 2 1 1 3 
Average 1.8 1.4 1 1.6 2.2 
 Table 3: Intensity scores. DSG-2 intensity scores of per group. 
 
FIGURE 2: DESMOGLIEN-2 EXPRESSIONS 
 
Figure 2: The expression of Desmoglein-2. Intensity: 0, none; 1, very weak; 2, weak, 3, moderate; 
and 4, strong:  Ctrl: Control, Low: Low dysplasia, High: high dysplasia, DOI: Depth of invasion 
(p values= 0.39 (ctrl/low), 0.064    (ctrl/high), 0.14 (low/high), 0.66 (ctrl/DOI<5), 0.53 





FIGURE 3: Immunostaining 
    
 Score 1                            Score 2                               Score 3                               Score 4 





Cell adhesion molecules are involved in many biological and physiological functions in 
human body. Adhesion molecules mainly maintain cell-cell and cell-matrix interaction and tissue 
architecture. (66) They are also involved in signal transduction, cell migration, cell cycle, and 
cell proliferation. (67) Cell adhesion molecules are involved in the process of many diseases, 
such as autoimmune disease, cardiomyopathy, and cancer.(67–69)  
Dsg-2 is expressed in cardiomyocytes and human epithelial cells and has been studied in 
cancer. Hutz et al revealed that the silencing of Dsg-2 in pancreatic cancer cells enhanced 
invasion and that Dsg-2 may act as a tumor suppressor. (31) 
Yashiro et al revealed that a decreased Dsg-2 expression is significantly correlated with 
loss of tumor differentiation in diffuse-type gastric carcinoma and the prognosis of patients with 
Dsg-2 negative tumors was worse than Dsg-2 positive tumors.(70) Peitsch et al showed that loss 
of Dsg-2 increased melanoma cell migration.(71)  
However, there are results claiming the opposite finding. Tan et al have claimed that Dsg-
2 is overexpressed in melanoma and mediates vasculogenic mimicry which leads to angiogenesis 
in the tumor.(72) Han et al have revealed that increased Dsg-2 levels are associated with tumor 
progression of hepatocellular carcinoma.(73)  
As for OSCC, Kume et al showed that Dsg-2 expression is downregulated in the OSCC 
cell line HSC-4.(74)  
On the other hand, Overmiller et al revealed the role of Dsg-2 molecules in the 
progression of head and neck squamous cell carcinoma. They showed that Dsg-2 was 
overexpressed in head and neck squamous cell carcinoma and that the processed fragment of 
22 
Dsg-2 modulates extracellular vesicles. This modulation potentially leads to tumor 
progression.(32)  
These conflicting study results can be confusing, however, some of the studies can 
explain the upward trend of the expression of Dsg-2 in OSCC as the DOI increases that is seen in 
our current study. Therefore it is possible that Dsg-2 either mediates tumorgenesis and 
progression or acts as a tumor suppressor.  
In this project, we have evaluated the role of Dsg-2 in OED and OSCC in order to better 
understand the biologic behavior of this type of epithelial malignancy.  We hypothesized that the 
decrease of Dsg2 expression was observed during tumor progression of OSCC and investigated 
the correlation between the its expression and OED and OSCC DOI. 
Even though our data did not reach statistical significance, our results revealed that there 
was progressive loss of Dsg-2 expression and intensity during OED advancement and subsequent 
progressive gain of expression and intensity with OSCC increased DOI. 
Kamekura et al revealed that loss of Dsg-2 in colonic epithelial carcinoma cells inhibited 
proliferation through the reduction of epidermal growth factor receptor (EGFR) signal 
transduction.  Their analyses of human colon cancers demonstrated increased Dsg2 protein 
expression.(75) Zhou et al showed similar results in a cervical cancer cell line where loss of Dsg-
2 reduced cell proliferation, migration and invasion via downregulation of mitogen-activated 
protein kinase (MAPK) signal transduction.(76)  
Based on these studies and our results, we suggest that Dsg-2 decreases during OED progression, 
whereas in the progression of OSCC it might be upregulated in order to enhance angiogenesis via 
vasculogenic mimicry. 
Dsg-2 has been studied less than Dsg-1 and Dsg-3 in various types of cancer. The role of Dsg-2 
in the progression of OED and OSCC is still unclear. More studies are needed to explore the 
23 
precise mechanisms that result in these alterations in expression.  The elucidation of these 
mechanisms can potentially lead to the development of targeted therapies that will improve the 
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